TY - JOUR
T1 - Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
AU - Su, Chaoyue
AU - Wang, Hui
AU - Liu, Yunru
AU - Guo, Qiaoru
AU - Zhang, Lingling
AU - Li, Jiajun
AU - Zhou, Wenmin
AU - Yan, Yanyan
AU - Zhou, Xinke
AU - Zhang, Jianye
N1 - Funding Information:
Funding. This work was supported by National Natural Science Foundation of China (81773888, U1903126, and 81902152) and Natural Science Foundation of Guangdong Province (2020A151501005 and 2020A1515010605).
Publisher Copyright:
© Copyright © 2020 Su, Wang, Liu, Guo, Zhang, Li, Zhou, Yan, Zhou and Zhang.
PY - 2020/9/17
Y1 - 2020/9/17
N2 - Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging results in first-line or second-line treatment of non-small cell lung cancer patients. Meanwhile, anti-PD-1/PD-L1 immune checkpoint drugs combined with other treatments, such as chemotherapy, targeted therapy as well as anti-CTLA-4 checkpoint therapy, are considered an attractive treatment with higher efficacy. However, toxicity associated with PD-1/PD-L1 blockade is worth attention. Understanding the adverse effects caused by anti-PD-1/PD-L1 immunosuppressive agents is vital to guide the clinical rational use of drug. In this review, we summarized the adverse effects that occurred during the clinical use of anti-PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer and discussed how to effectively manage and respond to these adverse reactions.
AB - Currently, immunotherapy has shown great efficacy in clinical trials, and monoclonal antibodies directed against immune checkpoint PD-1/PD-L1 have shown encouraging results in first-line or second-line treatment of non-small cell lung cancer patients. Meanwhile, anti-PD-1/PD-L1 immune checkpoint drugs combined with other treatments, such as chemotherapy, targeted therapy as well as anti-CTLA-4 checkpoint therapy, are considered an attractive treatment with higher efficacy. However, toxicity associated with PD-1/PD-L1 blockade is worth attention. Understanding the adverse effects caused by anti-PD-1/PD-L1 immunosuppressive agents is vital to guide the clinical rational use of drug. In this review, we summarized the adverse effects that occurred during the clinical use of anti-PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer and discussed how to effectively manage and respond to these adverse reactions.
KW - adverse effects
KW - immune checkpoint inhibitor
KW - immunotherapy
KW - non-small cell lung cancer
KW - PD-1/PD-L1
UR - http://www.scopus.com/inward/record.url?scp=85091917377&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85091917377&partnerID=8YFLogxK
U2 - 10.3389/fonc.2020.554313
DO - 10.3389/fonc.2020.554313
M3 - Review article
AN - SCOPUS:85091917377
SN - 2234-943X
VL - 10
JO - Frontiers in Oncology
JF - Frontiers in Oncology
M1 - 554313
ER -
